CCT241161
Cat. No.：YN350281
| 产品名称: | CCT241161 |
| CAS No.: | 1163719-91-2 |
| Chemical Name: | N-[4-[(3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-8-yl)oxy]-2-(methylthio)phenyl]-N'-[3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazol-5-yl]-urea |
| Synonyms: | CCT 241161 |
| 分子量: | 541.62536 |
| 分子式: | C28H27N7O3S |
| SMILES: | O=C1NC2=NC=CC(OC3=CC=C(NC(NC4=CC(C(C)(C)C)=NN4C5=CC=CC=C5)=O)C(SC)=C3)=C2N=C1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | CCT241161 是一种口服有效的泛型RAF抑制剂，其对LCK,CRAF,SRC,V600E-BRAF和BRAF的IC50值分别为 3, 6, 10, 15 和 30 nM。CCT241161 对BRAF和NRAS突变的黑色素瘤具有良好的活性。CCT241161 还具有抗癌细胞增殖活性。 |
| IC50和靶点: | [{name:"CRAF:6 nM (IC50)"},{name: "Braf:30 nM (IC50)"},{name: "BRafV600E:15 nM (IC50)"},{name: "SRC:0.01 μM (IC50)"},{name: "LCK:0.003 μM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Girotti, M.R., Lopes, F.J.P., Preece, N., et al.Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanomaCancer Cell31(3),85-96(2017)
